SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Company issued a press release reporting "corrected financial results" for the three and nine months ended March 31, 2026, in connection with filing an Amended Form 10-Q/A. This is a disclosure of quarterly financial results, which falls squarely within the earnings_release category. The fact that the results are "corrected" (implying a prior error) makes this material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on three proposals: election of seven directors, ratification of Wipfli LLP as independent auditor, and approval of a Stock Plan amendment to increase authorized shares by 200,000. All three proposals passed with clear majorities, and the disclosure includes detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) for each matter.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fuel Tech's Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes on three proposals: election of four directors (Vincent J. Arnone, Douglas G. Bailey, Sharon L. Jones, and Dennis L. Zeitler), ratification of RSM US LLP as independent auditor, and an advisory vote on executive compensation, with detailed vote tallies for each matter. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →The filing discloses the appointment of Yasir Haider as Chief Financial Officer effective June 3, 2026, a principal financial officer role. While James Clavijo's departure from the CFO position is mentioned, the principal disclosed action centers on Haider's appointment to this material executive position. CFO appointments are material to investors as they affect financial reporting oversight and governance.
View raw filing on EDGAR →Rick Dunn, the Chief Financial Officer, is stepping down from his position at the conclusion of a transition period following a mutual agreement with the Company. While the disclosure also includes severance terms (base salary continuation, COBRA, and RSU acceleration), the principal disclosed action is the departure of a named executive officer. The CFO role is material to investor assessment of the company's financial management and governance.
View raw filing on EDGAR →This Item 5.07 discloses the complete results of Appian's June 3, 2026 annual stockholder meeting, including voting outcomes on five proposals: election of eight directors, ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, frequency of future advisory compensation votes, and approval of the amended 2017 Equity Incentive Plan. The detailed vote tallies for each proposal and director nominee are material to investors assessing corporate governance and capital allocation decisions.
View raw filing on EDGAR →The filing discloses a delisting compliance matter under Nasdaq Listing Rule 5450(a)(1) regarding the Minimum Bid Price Requirement. Although the Company has now regained compliance as of June 5, 2026, the disclosure centers on the prior non-compliance notice (December 22, 2025) and the resolution of that delisting risk. This is a material event affecting the Company's listing status and investor confidence, even though the immediate threat has been resolved.
View raw filing on EDGAR →SI-BONE held its Annual Meeting of Stockholders on June 8, 2026, with shareholders voting on three proposals: election of directors (Jeffrey W. Dunn and John G. Freund, M.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of executive compensation. All three matters passed.
View raw filing on EDGAR →Groupon appointed Aditya Rajkumar as Chief Operating Officer, effective August 3, 2026, with a compensation package including a $500,000 base salary, cash bonuses, and equity awards of 155,000 shares.
View raw filing on EDGAR →The filing discloses the separation of Mannix Aklian, Chief Commercial Officer and Global Head of Software Sales and Marketing, formalized through a transition and separation agreement dated June 5, 2026. While the disclosure includes detailed severance and compensation terms, the principal disclosed action is Aklian's departure from the Company. The separation of a C-suite executive responsible for commercial operations and sales is material to investors' assessment of the registrant's leadership and business continuity.
View raw filing on EDGAR →The filing discloses a 1-for-40 reverse stock split effected on June 3, 2026, explicitly stated as being undertaken "solely to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market...and Nasdaq's $1.00 minimum bid price requirements." This is a classic delisting-risk mitigation action—the company's stock price had fallen below Nasdaq's minimum bid price threshold, triggering the need for a reverse split to avoid delisting. The materiality is clear: failure to maintain listing compliance would be terminal to the company's public status.
View raw filing on EDGAR →Volato Group entered into a Securities Purchase Agreement on June 7, 2026, to sell 6,500,000 shares of Class A common stock at $0.34 per share to institutional investors, raising approximately $2.21 million in gross proceeds. The filing explicitly discloses this under Item 1.01 (Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), with the securities offered in reliance on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement that materially increases share count and affects existing shareholders' ownership percentage.
View raw filing on EDGAR →The filing discloses entry into a material secured loan agreement (Item 1.01) with Agile Capital Funding, LLC on May 27, 2026, for approximately $260,000 borrowed with ~$389,740 total due over 32 weeks. While this creates a direct financial obligation (Item 2.03), it does not fit cleanly into the covenant_breach category (no breach alleged) or dilutive_issuance (debt, not equity). The subordinated nature and short repayment term suggest financial stress, but the event is best classified as a material financing arrangement outside the standard taxonomy.
View raw filing on EDGAR →Tonix announced entry into an agreement with a group purchasing organization (GPO) providing coverage for TONMYA® to approximately 17 million U.S. commercially insured individuals, effective June 1, 2026. This represents a significant commercial milestone for the company's product, expanding market access beyond the ~75 million Medicaid beneficiaries already covered. While this is a material commercial development affecting the company's market opportunity and competitive position, it does not fit neatly into the standard 8-K event taxonomy (not M&A, not an executive change, not a financial restatement or impairment), warranting classification as other_material.
View raw filing on EDGAR →The filing discloses the issuance of 109,588,265 shares of Class A common stock in exchange for 3,870,000 shares of Series C Preferred Stock on June 5, 2026. This represents a massive dilutive equity issuance that increased outstanding shares from approximately 55.3 million to 164.9 million—a nearly 3x increase. The stated purpose was to regain Nasdaq compliance and reduce stockholders' deficit, indicating financial distress. While technically an exchange rather than a cash raise, the economic substance is a highly dilutive issuance to existing shareholders.
View raw filing on EDGAR →Vivos Therapeutics received a Nasdaq notice on June 5, 2026, that it failed to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) from April 23 to June 4, 2026. The company has been granted a 180-day compliance period (until December 2, 2026) to regain compliance, with potential for a second 180-day period if certain conditions are met.
View raw filing on EDGAR →Vivos Therapeutics completed an unregistered private placement of a convertible promissory note (the "V-Co 4 Note"), exempt from registration under Section 4(a)(2) of the Securities Act, which is convertible into common stock and creates dilution to existing shareholders.
View raw filing on EDGAR →Ocean Power Technologies entered into a Securities Purchase Agreement on June 4, 2026, to sell 25,000,000 shares of common stock at $0.40 per share, together with 25,000,000 common warrants, for aggregate gross proceeds of $10.0 million. This is a registered direct offering of equity securities with significant dilution to existing shareholders. The warrants are exercisable at $0.40 per share and expire six years after initial exercise, further diluting equity. This is a classic dilutive equity issuance disclosed under Item 1.01.
View raw filing on EDGAR →The Company disclosed that the DOE reinstated a Grant and extended the project and budget periods. This represents a material positive development for a battery technology company — reinstatement of federal funding and project extension would affect investor assessment of the company's financial resources and operational runway. However, the Item 7.01 disclosure is deliberately non-specific about the grant amount, original terms, or financial impact, and the actual press release content is not provided in the excerpt. Without those details, the event does not fit cleanly into earnings_release, ma_activity, or other more specific categories, warranting classification as other_material.
View raw filing on EDGAR →Item 4.01 discloses that AOGB CPA Limited resigned as the independent registered public accounting firm of Society Pass Incorporated effective immediately on June 2, 2026. The filing explicitly states AOGB did not issue an audit opinion on the 2025 financial statements and confirms no disagreements or reportable events occurred. This is a clear auditor change event that would materially affect investor assessment of the company's financial reporting reliability.
View raw filing on EDGAR →The filing discloses under Item 4.01 that Assure CPA, LLC resigned as the Company's independent registered public accounting firm on June 3, 2026, following its merger into Sadler Gibb & Associates, LLC, and that Sadler Gibb was engaged as the new auditor on June 5, 2026. The filing explicitly states there were no disagreements or reportable events with the prior auditor, indicating a routine transition rather than a dispute-driven change. This is a classic auditor change event material to investors' assessment of financial reporting oversight.
View raw filing on EDGAR →The filing discloses entry into an underwriting agreement for a firm commitment underwritten offering of 592,270 shares of common stock and 292,135 warrants at $18.00 per unit, generating approximately $5.3 million in gross proceeds (or $6.1 million if the overallotment option is exercised). This is a material dilutive equity issuance under Item 1.01, with detailed warrant terms including exercise prices and reset provisions. The offering is expected to close June 9, 2026, and proceeds will fund development of NCT business, R&D, and general corporate purposes.
View raw filing on EDGAR →The filing discloses an unregistered private placement of convertible notes ($500,000 principal at the June 3, 2026 closing, with up to $3,000,000 authorized) and warrants to purchase common stock, made in reliance on Section 4(a)(2) and Regulation D Rule 506(b). The convertible notes convert into common stock at $1.60 per share, and warrants are exercisable at $1.75 per share, creating significant dilution. Item 3.02 explicitly confirms the unregistered sale of equity securities in a private placement.
View raw filing on EDGAR →Celcuity entered into an underwriting agreement on June 3, 2026, to issue $575 million aggregate principal amount of 0.250% Convertible Senior Notes due 2032 (including full exercise of a $75 million over-allotment option), convertible into common stock at an initial conversion price of approximately $124.53 per share. The offering raised approximately $557 million in net proceeds and creates substantial dilution potential for existing shareholders.
View raw filing on EDGAR →Celcuity completed a voluntary prepayment of approximately $137.5 million to fully satisfy and discharge its Amended and Restated Loan and Security Agreement with Oxford Finance and Innovatus Life Sciences, terminating all obligations under the facility and eliminating associated debt covenants.
View raw filing on EDGAR →Item 2.03 incorporates Item 1.01 by reference, disclosing a material transaction that creates direct financial obligations consistent with M&A activity or a significant change of control event.
View raw filing on EDGAR →The filing discloses a 1-for-5 reverse stock split effectuated via Certificate of Change filed June 2, 2026, becoming effective June 11, 2026. While reverse stock splits are structural corporate actions, this one is material to investors as it reduces outstanding shares from ~365 million to ~73 million and affects trading mechanics, stock option/RSU adjustments, and fractional share treatment. The event does not fit neatly into the specific taxonomy categories (not a bylaw amendment alone, not M&A, not an impairment), making "other_material" the most appropriate classification for this significant capital structure modification.
View raw filing on EDGAR →AOGB CPA Limited resigned as the Company's independent registered public accounting firm effective June 2, 2026, and was replaced by Barton CPA PLLC on June 4, 2026. This is a clear auditor change under Item 4.01. The filing discloses no disagreements or reportable events, suggesting a routine transition rather than a crisis-driven change, but the change itself is material as it affects the registrant's financial reporting oversight and audit continuity.
View raw filing on EDGAR →The filing discloses Item 2.02 (Results of Operations and Financial Condition) with a press release dated June 8, 2026 reporting financial results for the first quarter ended April 30, 2026. This is a standard earnings release disclosure, material to investors as it provides quarterly financial performance information.
View raw filing on EDGAR →The filing discloses the appointment of Andriy Mushak as fractional Chief Financial Officer effective June 6, 2026, following the departure of Alan Weichselbaum. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background information and compensation terms ($6,000/month via consulting agreement with LMAM Consulting Group). This is material as CFO changes affect investor assessment of financial reporting and governance.
View raw filing on EDGAR →The filing discloses the appointment of Andriy Mushak as fractional Chief Financial Officer effective June 6, 2026, following the departure of Alan Weichselbaum. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background information and compensation terms ($6,000/month). This is material as CFO changes affect investor assessment of financial reporting and governance.
View raw filing on EDGAR →Hongyu Zhou, Chairman of the Board of AiRWA Inc., resigned from the Board effective immediately on June 2, 2026. This is a clear executive departure of a senior officer (board chair). The filing explicitly states the resignation was not due to disagreement with the company, but the departure of a chairman is material to investors' assessment of corporate governance and leadership continuity.
View raw filing on EDGAR →The filing discloses non-reliance on previously issued financial statements spanning fiscal years 2024–2025 and multiple quarterly periods (Q1–Q3 2025, Q1 2026). The Board concluded on June 3, 2026 that audited and unaudited financial statements should no longer be relied upon due to material errors including misclassification of $7.1M in client funds, an $8.2M subscription receivable reclassification to contra-equity, intercompany elimination errors, and foreign currency translation adjustments. This is a classic Item 4.02 restatement disclosure with substantial corrections to assets, equity, and net income across multiple periods.
View raw filing on EDGAR →This 8-K discloses the completion of Aeon Acquisition I Corp.'s initial public offering (IPO) on June 4, 2026, with 12.5 million units sold at $10.00 per unit generating $125 million in gross proceeds, plus an additional $18.75 million from full exercise of the underwriters' over-allotment option. While technically an IPO rather than a traditional M&A transaction, the filing is structured around Item 1.01 (Entry into Material Definitive Agreements) and Item 3.02 (Unregistered Sales of Equity Securities), and the IPO represents a material capital-raising event that fundamentally changes the company's structure and capitalization. The company is a special purpose acquisition company (SPAC) formed to pursue an initial business combination, making this IPO disclosure material to investors.
View raw filing on EDGAR →Item 5.07 discloses the results of BTCS Inc.'s 2026 Annual Meeting of Shareholders held on June 8, 2026, including voting outcomes for director elections (Charles Allen, Charles Lee, Ashley DeSimone), auditor ratification (Forvis Mazars, LLP), and three equity plan amendments. All proposals passed, with director elections requiring plurality votes and other matters requiring majority approval. This is a material shareholder vote result disclosure as required by Item 5.07.
View raw filing on EDGAR →The filing discloses under Item 4.01 that Assure CPA, LLC resigned as the Company's independent registered public accounting firm on June 3, 2026, following its merger into Sadler Gibb & Associates, LLC, and that Sadler Gibb was engaged as the new auditor on June 8, 2026. This is a clear auditor change event. The materiality is heightened by the fact that the prior auditor's reports contained an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern.
View raw filing on EDGAR →Guangzhe Su disposed of his controlling block of shares (from 52.06% to less than 0.01%) and resigned from all officer and director positions, resulting in a change of control of the registrant. Shares were transferred to multiple new holders including Yan Li (10%), Yang Liu (10%), and others, fundamentally altering the company's ownership and control structure.
View raw filing on EDGAR →Xiangying Meng was appointed as Chairman and CEO (promoted from CFO) effective June 5, 2026, and two new directors (Yang Liu and Yong Yang) were appointed, following the resignation of Chairman/CEO Guangzhe Su and three directors as part of the change in control.
View raw filing on EDGAR →The company changed its corporate name from Brilliant N.E.V. Corp. to Origin Tea Inc. and implemented a 1-for-8 reverse stock split, both approved by the Board and stockholders and filed with the Nevada Secretary of State on June 7, 2026. The reverse stock split proportionately reduces authorized shares from 345 million to 43.125 million and materially affects share count and trading mechanics.
View raw filing on EDGAR →The Board approved a material strategic pivot to the tea industry, including incorporation of foreign subsidiaries (Origin Tea Industry Limited in Hong Kong and a wholly foreign-owned enterprise in China), relocation of principal executive offices to Hainan, and authorization of a private placement financing program. The company remains a shell company with no securities yet issued under the financing program.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from MariMed Inc.'s June 4, 2026 Annual Meeting of Stockholders. The filing reports the specific vote tallies for two proposals: election of four directors (Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.) and advisory approval of M&K CPAs PLLC as independent auditors for fiscal 2026. The detailed vote counts (FOR, WITHHELD, BROKER NON-VOTE for directors; FOR, AGAINST, ABSTAIN for auditors) are the core disclosure required under Item 5.07.
View raw filing on EDGAR →The disclosure concerns the conversion price of subordinated convertible notes due 2031, which affects the terms and potential dilution of an outstanding debt instrument. While the specific content is not provided, conversion price adjustments or resets on convertible securities are material to investors assessing capital structure and dilution risk, but do not fit neatly into the more specific event categories (not a new issuance under dilutive_issuance, not a covenant breach, and not exec/M&A activity). This is classified as other_material given its disclosure under Item 8.01 and relevance to the company's financial obligations.
View raw filing on EDGAR →Stockholders approved the Smart Sand, Inc. 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan on June 2, 2026, authorizing 2,400,000 new shares under the equity plan and 3,000,000 shares for the ESPP, along with forms of award agreements for restricted stock awards.
View raw filing on EDGAR →Smart Sand held its Annual Meeting on June 2, 2026, with stockholders voting on five proposals: election of two Class I directors (Sharon Spurlin and Timothy J. Pawlenty), ratification of Grant Thornton LLP as auditor, advisory approval of named executive officer compensation, approval of the 2026 Equity Incentive Plan, and approval of the 2026 Employee Stock Purchase Plan.
View raw filing on EDGAR →Avalo Therapeutics held its Annual Meeting of Stockholders on June 2, 2026, with voting results on three proposals: election of seven board directors, approval of the amended and restated 2016 ESPP, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →Nurix entered into a material License and Collaboration Agreement with Roche involving an exclusive worldwide license to develop and commercialize bexobrutideg. The transaction includes a $700 million upfront payment and up to $2.3 billion in total potential payments, with Nurix retaining co-development and co-commercialization rights in the U.S. and receiving royalties on ex-U.S. sales.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from SAIC's Annual Meeting of Stockholders held on June 3, 2026, covering five distinct matters: election of ten directors, say-on-pay advisory vote, say-on-pay frequency vote, 2023 Equity Incentive Plan share authorization increase, and auditor ratification. The filing presents final vote tallies for each proposal, which is the core content required by Item 5.07.
View raw filing on EDGAR →Rajiv Basu was appointed as a director and Audit Committee Chair of James River Group Holdings, Inc., effective June 8, 2026. Concurrently, director Dennis J. Langwell resigned effective June 16, 2026. The appointment of Basu to the board and Audit Committee chair position represents a material change to the company's governance structure.
View raw filing on EDGAR →GoHealth, Inc. and its subsidiaries filed voluntary petitions under Chapter 11 of the Bankruptcy Code on June 7, 2026, in the U.S. Bankruptcy Court for the District of Delaware, with the company operating as debtors-in-possession under a prepackaged chapter 11 plan of reorganization.
View raw filing on EDGAR →The Chapter 11 bankruptcy filing constitutes an event of default under two material debt agreements (Superpriority Senior Secured Credit Agreement and Credit Agreement), causing principal and accrued interest to become immediately due and payable.
View raw filing on EDGAR →